In-vitro and in-silico analysis of hesperidin and naringin for metabolic syndrome management

Abstract

This study evaluates the in-vitro and in-silico activities of hesperidin and naringin in the context of metabolic syndrome. The compounds were assessed for their inhibitory effects on key metabolic enzymes, including lipase, α-amylase, and α-glucosidase, as well as their antioxidant properties through assays such as DPPH free radical scavenging, ferrous ion chelation, and nitric oxide scavenging. Molecular docking analysis was performed to predict the binding affinities of hesperidin and naringin with these target enzymes. The results revealed that hesperidin and naringin exhibited significant lipase inhibitory activity, comparable to orlistat, and effective inhibition of α-amylase and α-glucosidase, comparable to the standard acarbose. The molecular docking findings supported the in-vitro enzyme inhibition results, highlighting the strong binding interactions of these compounds with the enzymes. Additionally, the pronounced antioxidant potential of hesperidin and naringin underscores their therapeutic relevance in managing metabolic syndrome.